

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 7

Complete if Known

Application Number	10/544,150
Filing Date	August 1, 2005
First Named Inventor	Francis X. Smith
Art Unit	1615
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	3009040 US01

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	1	US- 1,432,345	10-17-1922	W. W. Lasker	
	2	US- 2,976,576	03-28-1961	O. Wichterle et al.	
	3	US- 3,428,576	02-18-1969	Dickinson et al.	
	4	US- 3,429,576	02-25-1969	Yoshiaki Ikeda	
	5	US- 3,503,393	03-31-1970	R. E. Manley	
	6	US- 3,591,329	07-06-1971	Chromeczek et al.	
	7	US- 3,689,673	09-05-1972	Phares, Jr.	
	8	US- 3,755,561	08-28-1973	Rankin	
	9	US- 3,873,696	03-25-1975	Randeri et al.	
	10	US- 3,876,768	04-08-1975	Blank	
	11	US- 3,888,782	06-10-1975	Boghosian et al.	
	12	US- 3,910,296	10-07-1975	Karageozian et al.	
	13	US- 3,911,107	10-07-1975	Krezanoski	
	14	US- 3,912,450	10-14-1975	Boucher	
	15	US- 3,943,251	03-09-1976	Medow et al.	
	16	US- 4,022,834	05-10-1977	Gundersen	
	17	US- 4,029,817	06-14-1977	Blanco et al.	
	18	US- 4,046,706	09-06-1977	Krezanoski	
	19	US- 4,136,173	01-23-1979	Pramoda et al.	
	20	US- 4,136,175	01-23-1979	Rideout et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	21	GB 1,398,058	03-15-1973	Farmaceutisk		
	22	JP 58010517 A	01-21-1983	Santen Pharmaceutical		
	23	WO 91/01763	02-21-1991	Schering Corp.		
	24	WO 92/04905	04-02-1992	Abraham et al.		
	25	WO 92/11876	07-23-1992	Schering Corp.		
	26	WO 92/21049	11-26-1992	Allergan, Inc.		
	27	WO 94/00160	01-06-1994	Allergan, Inc.		
	28	WO 95/00176	01-05-1995	Allergan, Inc.		
	29	WO 96/06603	03-07-1996	Alcon Laboratories		

Examiner
Signature

/Tristan J. Mahyera/

Date
Considered

12/31/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.M./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 7

Complete if Known

Application Number	10/544,150
Filing Date	August 1, 2005
First Named Inventor	Francis X. Smith
Art Unit	1615
Examiner Name	Carlos A. Azpuru
Attorney Docket Number	3009040 US01

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	30	US- 4,136,534	01-30-1979	Villa	
	31	US- 4,209,817	06-24-1980	McGinnis	
	32	US- 4,354,952	10-19-1982	Reidhammer et al.	
	33	US- 4,361,458	11-30-1982	Grajek et al.	
	34	US- 4,361,548	11-30-1982	Smith et al.	
	35	US- 4,361,549	11-30-1982	Kung et al.	
	36	US- 4,394,381	07-19-1983	Sherrill	
	37	US- 4,439,417	03-27-1985	Matsunaga et al.	
	38	US- 4,525,346	06-25-1985	Stark	
	39	US- 4,599,360	07-08-1986	Fukami et al.	
	40	US- 4,748,189	05-31-1988	Su et al.	
	41	US- 4,758,596	07-19-1988	Ogunbiyi et al.	
	42	US- 4,783,488	11-08-1988	Ogunbiyi et al.	
	43	US- 4,820,352	04-11-1989	Reidhammer et al.	
	44	US- 4,826,879	05-02-1989	Yamamoto et al.	
	45	US- Re. 32,672	05-24-1988	Huth et al.	
	46	US- 4,836,956	06-06-1989	Ogunbiyi et al.	
	47	US- 4,863,900	09-05-1989	Pollock et al.	
	48	US- 4,891,423	01-02-1990	Stockel	
	49	US- 4,804,454	01-16-1990	Paradies	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	50	WO 97/34834	09-25-1997	Bio-Lab, Inc.		
	51	WO 97/41215	11-06-1997	Novo Nordisk A/S		
	52	EP 0 812 592 A1	12-17-1997	Kikkoman Corp.		
	53	JP 10-108899	04-28-1998	Tomey Technol Corp		T
	54	RU 2127100	03-10-1999	Borzenko et al.		T
	55	WO 99/23887	05-20-1999	Novo Nordisk A/S		
	56	WO 99/37295	07-29-1999	Devillez et al.		
	57	JP 2000016965 A	01-18-2000	Mitsubishi Gas		
	58	WO 00/07634	02-17-2000	NDT, Inc.		

Examiner
Signature

/Tristan J. Mahyera/

Date
Considered

12/31/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.M./

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/544,150
		Filing Date	August 1, 2005
		First Named Inventor	Francis X. Smith
		Art Unit	1615
		Examiner Name	Carlos A. Azpuru
		Attorney Docket Number	3009040 US01
(Use as many sheets as necessary)			
Sheet	7	of	7

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	124	BALLWEBER et al., "In Vitro Microbical Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against <i>Chlamydia trachomatis</i> ", Antimicrobial Agents and Chemotherapy, Jan. 2002, pp 34-41, Vol. 46, No. 1	
	125	CREIGHTON, THOMAS E., "Proteins Structures and Molecular Properties", W.H. Freeman & Co., New York, 1984, pp 179-182	
	126	DE LUCCA et al., "Fungicidal Properties, sterol binding, and proteolytic resistance of the synthetic peptide D4E1", Canadian Journal of Microbiology, June 1998, pp 514-520, Vol. 44, No. 6	
	127	KEAY, L., MOSER, P.W. and WILDO, B.S., "Proteases of the Genus Bacillus. II. Alkaline Proteases", Biotechnology & Bioengineering, March 1970, pp 213-249, Vol. XII	
	128	KEAY, L. and MOSER, P.W., "Differentiation of Alkaline Proteases from Bacillus Species", Biochemical and Biophysical Research Comm, 1969, pp 600-604, Vol. 34, No. 5	
	129	SCHUTTE, L., et al., "The Substitution Reaction of Histidine and Some Other Imidazol Derivatives With Iodine", Tetrahedon, Supp. No. 7, 1965, pp 295-308	

Examiner Signature	/Tristan J. Mahyera/	Date Considered	12/31/2008
--------------------	----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.M./